Project ARI

CART cells have the same immune system as patients (T lymphocytes) and are programmed genetically to selectively attack leukemic cells without adversely affecting healthy cells. The CART19 (CART cells against the CD19 molecule, which are characteristic of B-cell lymphocytes), here called ARI, have made it possible for refractory patients, those who do not respond to chemotherapy, to respond positively to the CART19. This procedure makes it possible to eliminate acute lymphoblastic leukaemia, which is resistant to conventional treatment.

With the support of family and friends and in conjunction with the Hospital Clínic de Barcelona, Ariana Benedé led a fundraising campaign in exemplary fashion and in solidarity with others to put this pioneering immunotherapy into practice. Ariana is the posthumous patron of the Glòria Soler Foundation.

Immunotherapy is currently revolutionising traditional oncological treatments, and its potential goes quite beyond the treatment of these tumours. There are many challenges yet to be faced, especially related to extending this type of therapy to other kinds of cancer, such as breast cancer and multiple myeloma.

UPDATE FEBRUARY 10, 2021

The Spanish Agency for Medicines and Health Products (AEMPS) has approved the CAR-T ARI-0001, developed by the Hospital Clínic, for use in patients over 25 years of age with lymphoblastic leukemia resistant to conventional treatments. It is the first CAR-T developed entirely in Europe to be approved by a regulatory agency.

The exceptional authorization of use by the AEMPS is a milestone in our country, as it is the first treatment with genetically modified cells that achieves it.

Read the full news at this link.

UPDATE JULY 22, 2024

CAR-T ARI0002h, developed at Hospital Clínic Barcelona-IDIBAPS, has been approved by the Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency for Medicines and Health Products (AEMPS) for approval as a non-industrially manufactured advanced therapy medicinal product for patients with relapsed multiple myeloma.

The AEMPS Committee’s approval is the step prior to the notification of the hospital exemption approval that Hospital Clínic Barcelona will receive in the coming days. The approval process from the hospital has been coordinated by the Clinical Pharmacology Service team, led by Dr Gonzalo Calvo.

Read the full news at this link.

MORTALES+ Community, Art and HIV/AIDS

Blue Soler Therapeutic SUP. Sport and Health

Vaccine against HIV/AIDS

Suñol Soler Collection

Josep Carreras Foundation

Gilead Sciences acquires investigational assets for the HIV vaccine designed at IrsiCaixa and driven by AELIX Therapeutics

Parc Sanitari de Sant Joan de Déu inaugurates the immersive experience ‘Mental State’ based on the works of artist Zush/Evru

Green light for CAR-T ARI0002h developed by Hospital Clínic-IDIBAPS for patients with multiple myeloma

The Glòria Soler Foundation presents ‘Peu i vernís’ by Antoni Tàpies at Clínic Barcelona/IDIBAPS as part of the Tàpies Year

Blue Soler leads first international project to demonstrate the therapeutic benefits of Stand Up Paddle (SUP)